

**DCF Psychotropic Medication Advisory Committee  
Meeting Notes.  
May 01, 2020, 1:00 PM**

**PRESENT via Video Conference or telephone conference call: Amy Veivia, PharmD; David Aresco RPh; Paul Rao, MD; Carissa Patsky-Pomerleau; Dr. Taylor DCF Director of Pediatrics.**

1. The meeting was held remotely: At 105PM Dr. Rao deferred the agenda to the June meeting as sufficient representation was not present. Attendees participated in some discussion as noted below.
2. The next meeting is scheduled for June 05, 2020 from 1pm – 2:30pm as a remote or live meeting depending on circumstances at that time.
3. Review of the minutes of the April 2020 meeting was deferred to the June 2020 meeting.
4. Announcements: NONE
5. Medication Therapeutic Class Review: DEFER. The antidepressant drug class will be reviewed in October 2020 and include CMCU data.
6. Old Business:
  - Form 465 Medication Request Form: DEFER.
7. New Business:
  - QTc prolongation risks with ziprasidone: are EKG's at baseline necessary? (DEFER)
  - Risks of weight gain/obesity with antihistaminic agents (hydroxyzine, diphenhydramine) and trazodone. DEFER pending additional research.
  - Obesity in foster youth. DEFER pending additional research.
8. Other as time allows:
  - After discussion it was recommended that the impact of COVID19 on services such as telemedicine, prescription filling, etc. (possibly bypassing CMCU) be discussed at the June 2020 meeting.
    - i. It was suggested that a guest speaker be invited regarding this issue perhaps reporting on any relevant DSS data (perhaps from Beacon). Beth Muller will be contacted to assist with this.
  - There was a short discussion regarding interagency variability.
9. Dr. Rao adjourned the meeting at 1:20PM.

Respectfully submitted: David S. Aresco Consulting Pharmacist